NAP1L1 and breast cancer: For example, RSF1 + B-C1, HSPA8 + B-C2, DEK + B-C3, ATRX + B-C4, RSF1 + Macro-C1, NAP1L1 + Macro-C2, DEK + Macro-C3, and ATRX + Macro-C4 were associated with a favorable immunotherapy response in BC (Fig. 5D).